Intracranial pressure management in severe intraventricular hemorrhage: A minireview

Abstract

Severe intraventricular hemorrhage (IVH) is a life-threatening neurological emergency that poses significant risks of morbidity and mortality, particularly due to the associated elevated intracranial pressure (ICP). Studies have shown that the incidence of IVH in very preterm infants is high, with management strategies playing a significant role in its development. Moreover, predictive models have been developed to forecast early mortality and severe IVH in very-low birth weight preterm infants, indicating the complexity and multifactorial nature of this condition. This mini-review synthesizes recent advances in the understanding of intracranial dynamics, monitoring technologies, and therapeutic strategies for managing ICP in IVH. The Monro-Kellie 4.0 framework integrates cerebrovascular autoregulation, intracranial compliance, and glymphatic clearance as core determinants of ICP. Pathophysiological mechanisms include obstructive hydrocephalus, hemoglobin-mediated neurotoxicity, and cortical spreading depolarizations. Advancements in non-invasive monitoring techniques, such as ICP monitoring and genetic testing, coupled with the integration of artificial intelligence, are significantly improving early detection capabilities and enabling more personalized management strategies. Therapeutic advances include algorithmic cerebrospinal fluid drainage, glymphatic-enhanced therapies, and precision hyperosmolar therapy. This review highlights the need for standardized protocols, large-scale trials, and artificial intelligence-driven approaches to improve outcomes in severe IVH.

Key Words: Intraventricular hemorrhage; Intracranial pressure; External ventricular drainage; Multimodal monitoring; Artificial intelligence; Glymphatic system

Core Tip: This mini-review provides an updated synthesis of intracranial pressure management in severe intraventricular hemorrhage, introducing the innovative Monro-Kellie 4.0 framework and highlighting the integration of artificial intelligence with multimodal monitoring for personalized care. It emphasizes emerging therapeutic strategies including glymphatic enhancement, smart drainage systems, and future research directions to improve patient outcomes through precision medicine approaches.

INTRODUCTION

Severe intraventricular hemorrhage (IVH), defined by a Graeb score ≥ 6, represents a critical neurological condition characterized by bleeding into the ventricular system, leading to elevated intracranial pressure (ICP), obstructive hydrocephalus, and secondary brain injury[1]. As a severe subtype of stroke, IVH carries high mortality rates and poor functional outcomes, presenting significant challenges in neurocritical care[2,3]. The management of ICP in these patients requires a sophisticated approach integrating pathophysiological understanding, advanced monitoring, and targeted interventions[4].

The incidence of IVH varies depending on underlying etiology, with hypertension, cerebral aneurysms, and vascular malformations representing common causes[5]. The condition typically presents with acute, severe neurological symptoms including sudden-onset headache described as “the worst headache of my life”, altered mental status ranging from confusion to coma, nausea/vomiting from ICP elevation, and focal neurological deficits depending on hemorrhage location and volume[6-9].

This mini-review aims to provide a comprehensive overview of current understanding and advancements in ICP management for severe IVH, focusing on theoretical models, pathophysiological mechanisms, monitoring techniques, therapeutic strategies, and future directions. We particularly emphasize the integration of novel technologies, particularly artificial intelligence (AI), and the application of personalized medicine approaches, which are revolutionizing the management paradigm for such challenging conditions.

THEORETICAL MODELS OF ICP DYNAMICS IN IVH

The conceptual framework for understanding ICP dynamics has evolved significantly from the classical Monro-Kellie doctrine to more sophisticated models that account for the complex pathophysiology of IVH[10]. The traditional Monro-Kellie principle, dating back to the 18^th century, posits that the cranial cavity functions as a rigid container with a fixed volume, in which the combined quantities of brain tissue, blood, and cerebrospinal fluid (CSF) must remain constant[8]. While this foundation remains relevant, contemporary understanding recognizes the dynamic nature of intracranial compensation mechanisms.

The updated Monro-Kellie 4.0 model represents a paradigm shift from viewing the intracranial space as a static container to understanding it as a dynamic system. This framework integrates three core physiological components: Cerebrovascular autoregulation (CA), intracranial compliance, and the glymphatic system[11]. In severe IVH, impairment of CA is a common and critical event, where cerebral blood flow (CBF) becomes passively dependent on systemic blood pressure, significantly increasing the risk of secondary brain injury and worsening outcomes[11,12]. The pressure reactivity index, derived from continuous monitoring of arterial blood pressure and ICP, has emerged as a crucial and validated parameter for quantifying the state of CA, with impaired autoregulation (a higher-pressure reactivity index) strongly predicting poor prognosis[13-16]. Concurrently, the glymphatic system, a brain-wide perivascular waste clearance pathway, plays a vital role in clearing toxic substances, including blood breakdown products and proteins implicated in neuroinflammation, from the brain’s interstitial and ventricular spaces. Its function is particularly promoted during sleep and is crucial for mitigating secondary injury[17]. Furthermore, the presence of blood in the ventricles triggers a massive inflammatory response, characterized by the release of cytokines and chemokines[18]. This inflammatory surge contributes strongly to vasogenic edema formation by disrupting the blood-brain barrier, which in turn might exacerbate increased ICP[11].

This advanced framework better captures the multifaceted nature of ICP regulation in IVH by integrating dynamic physiological processes, such as blood pressure fluctuations and secondary injuries, rather than focusing solely on static volume-pressure dynamics. The evolution of these conceptual models is summarized in Table 1.

Table 1 Evolution of the Monro-Kellie doctrine in intraventricular hemorrhage management.

Era	Core mechanism	Clinical applications	Key limitations in IVH
1.0 (1783-20th century)	Static volume compensation	CSF displacement to spinal compartment	Neglects compensatory thresholds and dynamic interactions
2.0 (2016)	Venous capacitance shifts	Jugular optimization during EVD clamping	Overlooks arterial inflow dynamics during autoregulatory failure
3.0 (2019)	Parenchymal deformation	Management of chronic hydrocephalus	Limited relevance to acute hemorrhage phases
4.0 (2025)	Integrated neurodynamics: CA + glymphatics + ICC	Predictive analytics for compliance failure	Requires advanced multimodal monitoring integration

IVH: Intraventricular hemorrhage; CSF: Cerebrospinal fluid; EVD: External ventricular drainage; CA: Cerebrovascular autoregulation; ICC: Intracranial compliance.

Mathematical modeling has provided valuable tools for simulating ICP dynamics in IVH and other various pathological conditions. Compartmental (lumped-parameter) models represent the intracranial space as interconnected chambers, with ventricles modeled as elastic structures with defined inflow (choroid plexus) and outflow (arachnoid villi) mechanisms[18]. For severe IVH, these models can simulate how clot mass occupies ventricular space and obstructs CSF pathways, leading to increased ICP and hydrocephalus. In severe cases of IVH, advanced models can replicate the obstruction of CSF pathways by clot mass within the ventricular space, resulting in elevated ICP. This simulation is crucial for understanding the progression of IVH and for developing effective treatment strategies.

The pressure-volume index model provides a method for predicting hemodynamic changes by assessing the relationship between volume alterations and pressure responses. More sophisticated poroelastic models incorporate tissue properties and fluid dynamics to simulate brain biomechanics[19]. While these mathematical models provide valuable theoretical frameworks and predictive capabilities, their clinical application remains limited by the complexity and individual variability of IVH pathophysiology[20].

MAIN PATHOPHYSIOLOGY OF ICP ELEVATION IN IVH

The elevation of in severe IVH results from a complex interplay of multiple pathological mechanisms. Understanding these processes is essential for developing effective treatment strategies and improving patient outcomes.

Obstruction of CSF pathways

The primary mechanism of ICP elevation involves obstruction of CSF pathways by blood clots. This obstruction can occur at various levels, including the foramina of Monro, the cerebral aqueduct, and the fourth ventricle outlets[20]. The resulting obstructive hydrocephalus leads to increased ventricular volume and elevated ICP, creating a dangerous cycle of increasing pressure and reducing cerebral compliance[21].

Inflammation and edema

The presence of blood in the ventricular system triggers a significant inflammatory response characterized by the release of cytokines and chemokines. This inflammatory cascade contributes to both vasogenic and cytotoxic edema, further exacerbating ICP elevation. Breakdown products of blood, particularly hemoglobin and iron, promote oxidative stress and neuronal injury through free radical formation[22]. These processes not only contribute to immediate ICP elevation but also establish conditions for delayed secondary injury[2,22].

Impaired cerebral autoregulation

Cerebral autoregulation, the brain’s ability to maintain stable CBF despite fluctuations in systemic blood pressure, becomes impaired in severe IVH[23]. This impairment involves both metabolic and neurogenic mechanisms. Elevated ICP can compress brainstem structures, interfering with vasomotor centers and leading to dysregulation of autonomic control. Additionally, inflammatory mediators and blood breakdown products can directly affect cerebral vessel responsiveness to autoregulatory signals[24,25].

In severe IVH, elevated ICP can compress the brainstem, interfering with the vasomotor centers and leading to dysregulation of autonomic control. Additionally, the release of vasoactive substances during inflammation can directly affect the responsiveness of cerebral bloodvessels to autoregulatory signals[6,10]. Such impaired autoregulation may lead to a condition termed “autoregulatory failure”, in which CBF becomes completely reliant on systemic blood pressure. This can result in either excessive CBF (hyperemia) or insufficient CBF (ischemia). Both situations are harmful and may contribute to a further increase in ICP and secondary brain injury[6,8].

Genetic and protein biomarkers in severe IVH and ICP elevation

There is also molecular pathogenesis involving toxin-mediated pathways in IVH, some of which may serve as therapeutic targets for elevated ICP[16-19]. The genetic factors influencing IVH susceptibility and severity are increasingly being recognized. Polymorphisms in genes associated with blood pressure regulation (angiotensin-converting enzyme, angiotensinogen), coagulation and fibrinolysis (plasminogen activator inhibitor-1, tissue-type plasminogen activator), and inflammatory mediators (interleukin-6, tumor necrosis factor-α) have been linked to an elevated risk and adverse outcomes in hemorrhagic events, including IVH[17,18].

Research has shown that these polymorphisms can influence the severity and prognosis of such condition. Genetic variations affecting vascular tone regulation, such as those in the endothelin receptor and angiotensin receptor genes, as well as antioxidant defense mechanisms like superoxide dismutase and catalase, may also influence ICP dynamics and treatment response. Protein biomarkers, such as S100B, neurofilament light chain, and glial fibrillary acidic protein (GFAP), offer critical insights into the severity and prognosis of neurological diseases. S100B, released by astrocytes in response to injury, correlates with ICP elevation and patient outcomes[13,19]. Neurofilament light chain, a component of the neuronal cytoskeleton, reflects axonal damage and correlates with the severity of injury[20].

Although no significant correlation between CSF hemoglobin, tumor necrosis factor-α, and GFAP in the first weeks of CSF diversion in neonates with IVH[26], and the peripheral blood levels of GFAP and S-100B were not significantly increased in very preterm infants that developed IVH[27], such biomarker as GFAP indicates astrocyte damage and gliotic responses and might be indicative of brain injury in IVH[21]. In a prospective longitudinal cohort study of liquid biopsy samples from 99 preterm neonates with IVH with explainable machine learning (ML) techniques - including statistical, regularization, deep learning, decision trees, and Bayesian methods, targeted proteomic analyses were conducted using serum and urine samples. Forty-one significant independent protein markers such as neurofilament light chain were identified as predictive of post-haemorrhagic ventricular dilatation development and survival. However, the targeted proteomics combined with ML need further validation for clinical implementation[27].

ICP MONITORING IN SEVERE IVH

Accurate monitoring of ICP is fundamental to effective management of severe IVH. The monitoring approaches have evolved from basic clinical assessment to sophisticated multimodal integration.

ICP monitoring modalities in severe IVH

Invasive intraventricular monitoring remains the gold standard, mostly with external ventricular drainage (EVD), which provides both therapeutic drainage capability and direct pressure measurement[22]. Modern EVD systems incorporate advanced features including integrated sensors, antibiotic-impregnated catheters to reduce infection risk, and automated drainage algorithms. The combination of EVD with intraventricular fibrinolysis has shown particular promise in managing IVH-related hydrocephalus[23].

Parenchymal fiberoptic monitors offer an alternative invasive approach with lower infection risk but lack therapeutic drainage capability[28]. These devices provide compartment-specific data but may suffer from measurement drift over time. The strategic placement of fiber optic sensors in targeted areas enhances their capability to monitor localized pressures, especially when used in conjunction with parenchymal hematomas[24].

Non-invasive monitoring techniques have advanced significantly, providing alternative options when invasive monitoring is contraindicated or not available. Transcranial Doppler ultrasonography assesses CBF velocity and pulsatility index, providing indirect ICP estimation and autoregulation assessment[25]. Optic nerve sheath diameter measurement, utilizing ultrasound, detects elevated ICP through changes in the optic nerve sheath, with sensitivity about 90% and specificity of 60%-85% respectively in acute settings[22,29-33], and the variations ranged from 0.12 mm to 3.30 mm per 5 mmHg change in ICP[34], but the structural variations, the quantitative quality and the dynamic change (event with across different ethnicities) restrict the clinical usage.

Emerging technologies include near-infrared spectroscopy which measures cerebral oxygenation, and other advanced imaging techniques that assess structural and functional correlates of ICP elevation[25,35]. Innovative approaches such as wireless multiparametric sensors and biodegradable ICP monitors are good for promising continuous monitoring without the need for removal procedures[36,37].

Since different modalities of ICP monitoring may be of with different advantages and limitations (Table 2), and there might be pressure gradient between different intracranial location, the multimodal monitoring can represent the current standard of care, integrating ICP with cerebral perfusion pressure (CPP), brain tissue oxygenation, and other physiological parameters[29]. This comprehensive approach enables individualized management based on specific pathophysiology rather than generic targets. The integration of AI and ML algorithms facilitates pattern recognition and predictive analytics, potentially allowing preemptive intervention before critical ICP elevation occurs[30].

Table 2 Comparative analysis of intracranial pressure monitoring techniques in severe intraventricular hemorrhage.

Technique	Accuracy	Advantages	Limitations	IVH-specific utility
EVD with ICP integration	Gold standard	Therapeutic drainage + monitoring	Infection risk (8%-15%), occlusion by clot	Enables thrombolytic administration, preferred for obstructive hydrocephalus
Parenchymal fiberoptic	± 2 mmHg	Low infection risk, compartment-specific data	Drift > 1 mmHg/day, no therapeutic function	Essential for large parenchymal extensions (> 15 mL)
ONSD ultrasound	Unstable, sensitivity 90%, specificity 60%-85%	Rapid bedside application	Overestimates ICP in acute hydrocephalus	Best for rapid triage when EVD unavailable
TCD pulsatility index	r = 0.68 with ICP	Autoregulation assessment	Operator-dependent, limited temporal windows	CPP titration during vasopressor use

IVH: Intraventricular hemorrhage; EVD: External ventricular drainage; ICP: Intracranial pressure; ONSD: Optic nerve sheath diameter; TCD: Transcranial Doppler; CPP: Cerebral perfusion pressure.

THERAPEUTIC INTERVENTIONS

The management of elevated ICP in severe IVH requires a multifaceted approach combining medical, surgical, and emerging therapeutic strategies.

Medical management

Medical management, which involves a bundle of treatment such as sedation, target temperature management and hyperosmolar therapy, forms the foundation of ICP control[10,38-41]. Sedation and neuromuscular blockade reduce the metabolic demand and prevent the increases in ICP from agitation or ventilator dyssynchrony[32]. Propofol and midazolam are commonly used sedatives, while vecuronium or cisatracurium provide neuromuscular blockade. However, careful titration is essential to avoid complications such as hypotension and prolonged weakness.

Blood pressure management maintains CPP while avoiding excessive hypertension that could increase bleeding risk or edema formation. The optimal CPP target may vary based on autoregulatory status, with personalized targets determined through continuous autoregulation monitoring, as evidenced by clinical studies. However, the optimal value of ICP or CPP is still controversial, even with the consensus of elective bundle management[4,35,42].

Hyperosmolar therapy, utilizing either mannitol or hypertonic saline, establishes an osmotic gradient that effectively decreases brain water content, as demonstrated in various studies comparing the effects of different concentrations of these agents[4,35,42,43]. The choice between agents depends on volume status, renal function, and electrolyte balance. Recent advances also include precision administration guided by volume status and continuous monitoring of serum osmolarity[4,44].

Surgical interventions

EVD remains the primary surgical intervention, offering both monitoring and therapeutic functions. Modern EVD systems incorporate advanced features including gravimetric systems, integrated monitoring, and safety mechanisms to prevent over-drainage[11,40,45]. In a prospective study of 52 patients with severe IVH, patients in the EVD with lumbar drainage group showed an 82% favorable (activities of daily living 1-3 score) prognosis after 3 months, which was significantly better than that of EVD alone (54%) without severe complications[40]. The combination of EVD with Ommaya drainage has been shown to be both safe and feasible for the treatment of IVH. The use of intraventricular fibrinolysis with either tissue-type plasminogen activator or urokinase in conjunction with EVD has been shown to improve clot clearance and decrease the duration of drainage[46,47].

Neuroendoscopic surgery offers minimally invasive clot evacuation under direct visualization[48,49]. This approach allows precise removal of obstructive clots while minimizing tissue damage. Recent technical advances include improved visualization systems, specialized instruments for clot removal, and navigation integration for optimal trajectory planning[49].

Decompressive craniectomy (DC) serves as a crucial salvage procedure for severe IVH complicated with refractory ICP elevation or massive cerebral edema despite maximal previous medical therapy[50-52]. Its efficacy across various deep hemorrhage locations is supported by the SWITCH trial[53]. Successful outcomes depend on appropriate patient selection, early surgery, a standardized large bone flap, and comprehensive perioperative management[10,11,52,53]. In cases with significant intraventricular cast, combining DC with EVD and fibrinolytics (per CLEAR-III insights) enhances clot clearance and may reduce shunt dependency. Although DC consistently lowers mortality, its effect on long-term functional recovery requires further investigation, highlighting the need for research into selection biomarkers, combined procedures, and ultra-early cranioplasty[10,11,52,53].

Emerging therapies

Glymphatic-enhanced therapies represent a novel approach targeting the brain’s waste clearance system[7,11,17]. Techniques including sleep modulation, specific body positions, and pharmacological enhancement show promise in improving clearance of blood products and reducing ICP. Anti-inflammatory agents target the neuroinflammatory response to intraventricular blood[7,11,17]. Phototherapy with photo-improvements of lymphatic drainage and clearing functions for IVH, the minocycline with its anti-inflammatory and neuroprotective properties, has shown promise in preclinical studies[54,55]. Interleukin-1 receptor antagonists represent another promising approach.

Iron chelation therapy represents a promising therapeutic strategy aimed at mitigating secondary brain injury following severe IVH. The core mechanism involves sequestering toxic free iron released from the breakdown of hemoglobin, which otherwise drives robust oxidative stress and neuronal damage. While traditional chelators like deferoxamine have shown potential, their clinical translation for central nervous system applications is limited by poor blood-brain barrier penetration and pharmacokinetic challenges. Emerging solutions focus on advanced drug delivery systems; for instance, encapsulating deferoxamine within chitosan-based nanocomposites has demonstrated enhanced drug loading, sustained release profiles, and improved cellular permeability in preclinical models, offering a viable pathway for effective brain targeting[56]. The deletion of microRNA-9-2 leads to embryonic cerebral hemorrhages and severe hydrocephalus and disrupting gene networks across a wide range of cell types in the developing brain, indicating the possible underappreciated and significant contributor to, and possibly as a therapeutic target for the disorder such as IVH[57].

FUTURE RESEARCH DIRECTIONS

The management of ICP in severe IVH continues to evolve with several promising research directions emerging. Advanced monitoring technologies with the multimodal monitoring (such as the cerebral microdialysis, intracranial electroencephalography and continuous biomarker assessment), wearable sensors, and implantable devices promise to transform patient management[4,58]. These technologies enable real-time assessment and remote monitoring, potentially facilitating earlier intervention and personalized treatment adjustment[59]. Personalized medicine approaches based on genetic profiling, biomarker status, and individual pathophysiology offer potential for optimized treatment[41]. Pharmacogenomic studies may guide drug selection and dosing based on individual metabolic characteristics and receptor polymorphisms. The new idea of AI and ML applications are rapidly advancing, offering predictive analytics, pattern recognition, and decision support[60]. These ideas and technologies can integrate multimodal data streams to identify early warning signs, predict treatment response, and optimize management strategies[61-63].

Novel therapeutic targets including microRNAs, exosomes, and targeted drug delivery systems represent promising avenues for intervention. These approaches offer potential for highly specific interventions with reduced side effects compared to conventional therapies. Large-scale clinical trials that prioritize patient-centered outcomes, including functional recovery, quality of life, and long-term cognitive function, are essential to advance the field, as they reflect the direct benefits and experiences of patients. Standardized protocols and collaborative networks will facilitate adequate recruitment and generalizable results. Global health initiatives addressing disparities in access to advanced monitoring and treatments are crucial for improving outcomes worldwide[46]. Simplified protocols, task-shifting approaches, and affordable technologies can make advanced care accessible in resource-limited settings.

CONCLUSION

The management of ICP in severe IVH has evolved significantly from basic concepts to sophisticated multimodal approaches, as evidenced by recent advancements in clinical scoring systems and the utilization of EVD techniques. The integration of advanced monitoring, targeted interventions, and personalized medicine strategies offers promise for improved outcomes in this challenging condition.

The Monro-Kellie 4.0 framework provides a comprehensive conceptual model incorporating CA, intracranial compliance, and glymphatic function. This advanced understanding facilitates targeted interventions addressing specific pathophysiological mechanisms rather than simply reacting to pressure elevations. Emerging new ideas of AI and technologies including ML, advanced imaging, and novel monitoring devices are transforming patient management. These innovations enable predictive analytics, personalized treatment, and continuous assessment beyond what was previously possible.

Future progress will depend on continued research, technological innovation, and global collaboration. Large-scale clinical trials, which are pivotal in transforming clinical medicine from experience-based to evidence-based, are instrumental in addressing healthcare disparities and improving outcomes for patients with severe IVH. These trials, conducted with rigorous quality control measures and involving multidisciplinary teams, ensure that the results are both reliable and applicable to a broad patient population.